The disclosure relates to a composition comprising a pharmaceutically effective amount of an opioid agonist and Compound-1, also known as samidorphan or ALKS 33. The opioid agonist may be buprenorphine, morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine or tramadol. The composition may be used to treat a depressive disorder.